Invest In PlantPharm BioMed
PlantPharm BioMed is seeking investors that are passionate about biotechnology and contributing to a more robust and sustainable healthcare system globally.
PlantPharm BioMed will TRANSFORM the Delivery of Vaccines through its proprietary plant-based replication platform that will allow for development of shelf-stable Oral Solid Dose vaccines delivered in the form of pills for humans, and pelletized feed for animals - wild, farmed and domestic.
The platform produces dramatically higher yields, substantially reducing costs to consumers, and eliminates ‘the jab’ from hypodermic needles. The product eliminates the need for refrigeration throughout the supply chain, expanding the reach to global markets.
PlantPharm BioMed grew the world’s first crop of plants containing Hepatitis B vaccine. The plant-based vaccine completed a successful human clinical trial of a vaccine delivered in an oral solid dose format. This trial provided proof of the benefits the new technology could bring to the pharmaceutical industry.
The pandemic of 2020 created a unique awareness and interest in vaccines globally. This highlighted an opportunity for improving the delivery and cost structure of human and animal vaccines, which PlantPharm BioMed is uniquely positioned to address.
